ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2936

Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis

Silvia Laura Bosello1, Enrico De Lorenzis1, Gerlando Natalello2, Giovanni Battista Canestrari1, Laura Gigante1, Lucrezia Verardi1, Ludovica Berardini3 and Elisa Gremese1, 1Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 2Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 3Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: gastrointestinal complications, interstitial lung disease, prognostic factors, pulmonary fibrosis and systemic sclerosis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is common in SSc and micro-aspiration of both acid and non-acid gastroesophageal reflux could be involved in the pathogenesis of ILD. Esophagogastroduodenoscopy (EGD) is an essential tool to evaluate disease severity of upper gastrointestinal tract involvement in SSc. The objective of the present study is to assess the role of EGD in predicting pulmonary functional deterioration in SSc patients.

Methods: One hundred and fifty patients with SSc and suspected esophageal involvement underwent EGD. Pulmonary function tests were performed at baseline and after a 36-months follow-up. Patients were characterized for disease phenotype, BMI, smoking exposure and medication history. A significant ILD progression was defined as a relative decline ≥10% of FVC or a concomitant decline ≥5% of FVC and ≥15% of DLCO.

Results: One hundred and thirty-six patients (90.5%) were female with a mean age of 55.6 ± 13.8 years and 12.1% were active smokers. Fifty patients (33.3%) had a diffuse cutaneous disease; 37.4% and 40.8% were positive for anti-centromere and anti-Scl70 antibodies respectively. The mean disease duration from the first non-Raynaud symptom was 5.9±6.7 years. Sixty-one patients (40.8%) showed EGD signs of reflux esophagitis. Among them, 31.3% had an erosive form (9.5% grade A, 15.6% grade B, 4.8% grade C and 1.4% grade D according to Los Angeles classification). At the baseline, 23.1% of the patients had a FVC≤80% and 45.6% had a DLCO≤50%. Patients with erosive esophagitis did not differ in terms of sex, age, duration and disease variant, positivity for anti-centromere, skin score values, FVC and DLCO at baseline compared to patients without erosions, but had a lower prevalence of anti-Scl70 (28.3 vs 52.5%, p=0.005) and active smoking (20.0 vs 8.4%, p=0.05). At follow-up, patients with esophageal erosions showed a greater relative decrease in FVC (3.4%±9.3% vs 1.7%±12.0%; p=0.013) without significant differences in the DLCO change. Overall, 11.0% of patients presented pulmonary disease progression. The presence of esophageal erosions was associated with a significantly greater risk of lung disease progression (OR 5.3, 95% CI 1.7-16.8, p=0.004) after paired correction for sex, age, duration of disease, auto-antibodies, skin involvement variant, baseline FVC and DLCO, smoke exposure and therapy with immunosuppressants, proton pump inhibitors, prokinetics, antiplatelet agents and prostanoids.

Conclusion: SSc patients with erosive esophagitis present a higher risk of progression of interstitial lung disease. This evidence supports a role of micro-aspiration of gastric contents in the development of inflammation and fibrosis of the airways.


Disclosure: S. L. Bosello, None; E. De Lorenzis, None; G. Natalello, None; G. B. Canestrari, None; L. Gigante, None; L. Verardi, None; L. Berardini, None; E. Gremese, None.

To cite this abstract in AMA style:

Bosello SL, De Lorenzis E, Natalello G, Canestrari GB, Gigante L, Verardi L, Berardini L, Gremese E. Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/esophageal-erosion-predicts-progression-of-lung-disease-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2018

ACR Meeting Abstracts - https://acrabstracts.org/abstract/esophageal-erosion-predicts-progression-of-lung-disease-in-patients-with-systemic-sclerosis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology